Anti-Obesity Drugs

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1.Industry Overview
Current & Future Analysis
Factors Influencing the Market
Obesity - A Global Epidemic
Table 1: Global Overweight Prevalence (2006):
Overweight Population (%) of Select Countries
(includes corresponding Graph/Chart)
Table 2: Abdominal Obesity Prevalence (%) by Region
and Sex (includes corresponding Graph/Chart)
Trends and Issues
Obesity: An Unmet Medical Need
Rising Demand for Obesity Therapeutics
Barriers to Development of Effective Drugs
New Research Aids in Discovery of Novel Drugs
Growing Problem of Obesity in Asia
Particularly China
2.Competition
Roche Leads the Race
Table 3: Leading Brands in the Global Anti-obesity Drugs Market (2007): Percentage Share Breakdown of Revenues
for Xenical/orlistat, Reductil/Meridia (sibutramine),
Alli, Acomplia and Others (includes corresponding
Graph/Chart)
Competition Grows with Pipeline Drugs
Current Anti-Obesity Drugs in Pipeline: 2008
3.Obesity - An Introduction
Diagnosis of Obesity
BMI Calculation and Classification
Waist Circumference and BMI
Causes of Obesity
Unhealthy Eating Habits
Environmental and Genetic Factors
Sedentary Lifestyle
Alcohol Intake
Childhood Obesity
Psychological Factors
Pregnancy
Hormonal Disorders
Drugs
Aging
Risks Associated with Obesity
4.Obesity Treatment
Dietary Therapy
Exercise Therapy
Behavior Therapy
Pharmacotherapy
Weight Loss Surgery
Invasive Vis-à-vis Non-invasive Procedures
A Brief Review of Select Invasive Procedures
Bariatric Surgery
Laparoscopic Adjustable Gastric Banding
Vertical Banded Gastroplasty (VBG)
Roux-en-Y Gastric Bypass Procedure (RYGB)
Lap-Band Procedure
Gastric Band Procedure
Gastric Bypass Procedure
Doudenal Switch
Prescription Drugs Vis-à-vis Non-Prescription Drugs
Table 4: Obesity Treatment Options and
Corresponding Success Rate
5.Anti-Obesity Drugs- An Insight
Introduction
Mechanism of Action
Review of Available Drugs
Phentermine
Sibutramine
Orlistat
Anti-obesity Drugs, Brands and Mechanism of Action
Table 5: Global Anti-obesity Prescription Drugs Market (2006): Percentage Share Breakdown of Prescriptions by Physician
Practices - Primary Care Physicians (PCP), Internal Medicine, Obsterics/Gynecology, Endocrinology/Diabetes,
Psychiatry/Neurology,
Cardiology and Others (includes corresponding Graph/Chart)
Review of Select Drugs Awaiting approval / Under Trials
6.Recent Clinical Trials
Genaera Initiates First Human Trial of Trodusquemine
Neurogen Completes First Trial of NGD-4715
Alizyme Secures USFDA Approval for Cetilistat Trials
GW Pharma to Start Human Trials of
New Anti Obesity Drug
Epix Completes Phase Ib Trial of PRX - 07034
7TM Pharma Starts Phase I/II Trial of TM30339
Arena Starts Phase III Clinical Trials of Lorcaserin
Drug Induced Serotonin Could Promote Weight Loss
Takeda Initiates Phase II Clinical Trials of ALT-962
Glenmark to Commence Phase I Trial of
New Anti-Obesity Drug
Amylin-Leptin Integrated Therapy to Treat Obesity
Vivus Completes Phase II Trial of Qnexa
VERNALIS Starts Phase I trial for Obesity
7TM Pharma Completes Phase I/ II Clinical Trials of
TM30338
Manhattan Pharmaceuticals Starts Phase I trial of
Oleoyl estrone
Arena Completes Phase2b Trials of APD356
Metabolic Accomplishes Phase 2b Trials of AOD9604
7.Product Approvals/Launches
Sanofi-Aventis Receives Swiss Approval for Acomplia
Zydus Cadila Introduces Slimona
Torrent Introduces Rimoslim
Gencor Introduces Slimaluma
Orexigen Develops Excalia
Scripps Research Institute Develops Vaccine for Obesity
Sanofi-Aventis Receives Approval to Market
Obesity Drug in EU
Sanofi-Aventis Rolls Out Acomplia
Sanofi Secures Approval for Acomplia in the UK
Novo Nordisk to Develop Anti-obesity Drug
Sanofi-Aventis Receives Approval to Market
Acomplia in Mexico
Ind-Swift Introduces Sibuslim-10
Wellnx Launches NV
Iron-Tek Introduces Appetite Suppressant
Yamanouchi and Keio University Discover Target
Molecule for Developing Anti-obesity Drug
8.Recent Industry Activity
Pfizer Halts CP-945, 598 Development
Shionogi to Acquire Sciele Pharma
Anthill Inks Agreement with Zafgen
EMEA Suspends Acomplia
GlaxoSmithKline to Sell Alli as OTC Drug
Sanofi-Aventis to Market Acomplia in UK
Orexigen Receives 4th US Patent for Contrave
BELLUS Health to Acquire Innodia
Ore Secures License to Develop Romazarit
GlaxoSmithKline Receives FDA Approval for Orlistat
Pfizer Receives Approval for Slentrol
GlaxoSmithKline Secures Licensing Rights of Orlistat
Pfizer Collaborates with Bristol-Myers Squibb
Takeda Collaborates with LG Life Sciences
Takeda to Acquire Paradigm
Sanofi-Aventis Secures Reimbursement Status
for Acomplia
AstraZeneca Inks Agreement with Palatin Technologies
Switzerland Includes Acomplia in Reimbursement List
Allergan Pockets EndoArt
Sanofi-Aventis Receives Approval for Acomplia
in Brazil
Biocon Inks MoU with Neopharma
Aurigene Partners with Forest Laboratories
Pfizer Licenses Obesity Compounds from Bayer
Pharmaceuticals
Merck Terminates Collaboration with Nastech
Sanofi-Aventis to Receive Rights for Rimonabant
UMN Pharma Inks Agreement with Crucell and
DSM Biologics
7TM Pharma Pockets CareX SA
BioLineRx Inks Licensing Agreement with Yissum
Aegis Inks Licensing Agreement with Albany
Medical College
Manhattan’s Obesity Drug Approved for Human Trials
Chugai Halts Development of Anti-Obesity Agent
HSG Acquires Polymann
Orchid Pockets Bexel
9.Focus on Select Players
Abbott Laboratories (US)
Alizyme Plc (UK)
Amylin Pharmaceuticals, Inc. (US)
AstraZeneca Plc (UK)
F. HOFFMANN-LA ROCHE LTD. (Switzerland)
GlaxoSmithKline Plc (UK)
Sanofi-Aventis SA (France)
SuperGen, Inc. (USA)
Takeda Pharmaceutical Company Limited (Japan)
VIVUS, Inc. (US)
10.Global Market Perspective
Table 6: World Recent Past, Current & Future Market Analysis for Anti-Obesity Drugs by Geographic Region - US, Europe
and Rest of World Independently Analyzed with Annual
Sales Figures in US$ million for Years 2005 through
2015 (includes corresponding Graph/Chart)
 Table 7: World 10-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Europe and Rest of World Markets for Years 2006,
2009 and 2015 (includes corresponding Graph/Chart)
III. MARKET
1.The United States
A. Market Analysis
Market Overview
Table 8: Leading Product Segments in the US Weight Loss Market (2008E): Percent Share Breakdown of Revenues for Diet
Drinks, Health Clubs, Bariatric Surgery, Diet Foods, Artificial Sweeteners, Weight Loss Centers, Medically Supervised Programs,
Meal Replacements & Appetite Suppressants, Prescription Drugs, Low Calorie Diet Programs and Others (includes corresponding
Graph/Chart)
Obesity Catching Them Young
New Drugs to Rule the Market
37 States Experience Increase in Adult
Obesity Rate
Statistical Data
Table 9: US Obesity Rate (2007): Prevalence
Rate of Leading States
Table 10: US Obesity Prevalence Estimates and Forecasts (2006-2020) (includes corresponding Graph/Chart)
Table 11: US Overweight Prevalence (1998 & 2002): Breakdown of Adult population by Category -
Overweight and Obese
Table 12: US Obesity Prevalence (2005-2006): Breakdown of Population (%) by Sex and Age Group (includes corresponding
Graph/Chart)
Table 13: US Anti-obesity Drugs Market (2006 &
2007): Number of Obese People Treated
in Million
Reimbursement Scenario
Regulatory Environment
Insufficient Regulatory and Enforcement Laws
Obesity and Related Ailments: Burden on Societal and
Economic Cost
Competition
Table 14: US Anti-obesity Drugs Market (2006 and 2007): Percentage Share Breakdown of Revenues by Brand - Meridia, Xenical
and Others (includes corresponding Graph/Chart)
Recent Clinical Trials
Product Approval/Launches
Strategic Corporate Developments
Review of Major Players
B. Market Analytics
Table 15: US Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed
with Annual Sales Figures in US$ million
for Years 2005 through 2015 (includes
corresponding Graph/Chart)
2.Europe
A. Market Analysis
Market Overview
Lack of Reimbursement: Barrier to Market
Growth
Statistical Data
Table 16: Obesity Prevalence (2007) in Select European Union Countries: Obesity Rates by Gender
(includes corresponding Graph/Chart)
Table 17: Europe Obesity Prevalence (2007) by Gender and Age Category (in 000s) (includes corresponding Graph/Chart)
Overview of Novel Policies Adopted by Select European
Countries to Prevent Obesity
B. Market Analytics
Table 18: European Recent Past, Current & Future
Analysis for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and
Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million
for Years 2005 through 2015 (includes
corresponding Graph/Chart)
Table 19: European 10-Year Perspective for Anti-Obesity Drugs by Geographic Region/Country - Percentage Breakdown of Dollar
Sales for France, Germany, Italy,
UK and Rest of Europe Markets for Years 2006, 2009
and 2015 (includes corresponding Graph/Chart)
2a.France
A. Market Analysis
Market Overview
Changing Lifestyle Alter Health Profile
Product Approval/Launches
Strategic Corporate Developments
Sanofi-Aventis SA - A Key Player
B. Market Analytics
Table 20: French Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2005
through 2015 (includes corresponding Graph/Chart)
2b.Germany
A. Market Analysis
Table 21: German Anti-obesity Drugs Market (2005 and 2006): Percentage Share Breakdown of Volume Sales by Leading Brands
- Meridia and Xenical and Others
B. Market Analytics
Table 22: German Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2005
through 2015 (includes corresponding Graph/Chart)
2c.Italy
Market Analysis
Table 23: Italian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2005
through 2015 (includes corresponding Graph/Chart)
2d.The United Kingdom
A. Market Analysis
Market Overview
Table 24: UK Childhood Prevalence (1995-2005): Percentage of Obese Children Aged 2-15 years
(includes corresponding Graph/Chart)
Recent Clinical Trials
Product Approval/Launches
Strategic Corporate Developments
Review of Major Players
B. Market Analytics
Table 25: UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2005
through 2015 (includes corresponding Graph/Chart)
2e.Rest of Europe
A. Market Analysis
Recent Clinical Trials
Product Approval/Launches
Strategic Corporate Developments
F. HOFFMANN-LA ROCHE LTD. - A Key Player
B. Market Analytics
Table 26: Rest of Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes
corresponding Graph/Chart)
3.Rest of World
A. Market Analysis
Brief Review of Select Regions
Canada
Table 27: Canadian Obesity Prevalence
(1979 & 2004): Obesity Rate by Age Group
 (includes corresponding Graph/Chart)
Table 28: Canadian Adult Overweight and Obesity Prevalence (2004): Breakdown of Population
(in 000s) by Sex
Asia-Pacific
Australia
Table 29: Prevalence Rate (%) of overweight/obese Students in Australia (includes corresponding Graph/Chart)
China
India
Drugs Under Development by Indian
Companies
Japan
Takeda Pharmaceutical Company Limited -
A Key Player
Korea
Use of Diet Pills Lack Proper Monitoring
New Zealand
Recent Clinical Trials
Product Approval/Launches
Strategic Corporate Developments
B. Market Analytics
Table 30: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes
corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE